NEUROBiOGEN

본문 바로가기 주메뉴 바로가기

Comunications

NEUROBIOGEN has been working with an advisory network of researchers and clinical
experts specializing in brain & neurological diseases with long experience.

News

News
Notice

News

Here are news on NEUROBIOGEN (currently in Korean only).

NO	SUBJECT	DATE	VIEW
107	CNR Research and Neurobiogen Collaborate on Clinical Trial of Alzheimer's New Drug Candidate 'Tisolaziline'.	2024. 09. 19	138
106	CNR Research, Neurobiogen Collaborate on Clinical Trials of New Drug Candidates for Alzheimer's and Obesity Treatments.	2024. 09. 19	80
105	100 Billion Won Investment Obesity Drug Enters Phase 2... Neurobiogen's Perseverance.	2024. 09. 09	97
104	Neurobiogen. Obesity Treatment Phase 2 Clinical Trial Receives IND Approval from Ministry of Food and Drug Safety.	2024. 09. 04	141
103	Neurobiogen, Obesity Treatment Approved for Phase 2 Clinical Trial… “Speeding Up Innovative New Drug Research”.	2024. 09. 04	91
102	Neurobiogen, New Drug Candidate 'KDS2010' Dementia and Obesity Phase 2a IND Approval.	2024. 09. 04	185
101	Neurobiogen, enters phase 2 clinical trial for Alzheimer's drug candidate.	2024. 09. 02	94
100	Neurobiogen, "Succeeded in Phase 1 of Obesity and Dementia Treatment..."Discussion on Global Big Pharma Technology Transfer"	2024. 07. 22	157
99	"Wigobi there"...BioVenture Speeds Research on Native Obesity Drugs.	2024. 03. 26	294
98	Kim Sang-wook, CEO of Neurobiogen, said, "We will promote the transfer of technology and treatment for dementia and obesity".	2024. 03. 20	331

1 2 3 4 5